about
Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectivesExercise Training in Group 2 Pulmonary Hypertension: Which Intensity and What Modality.EACPR/AHA Joint Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations.Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group.The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study.Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI Score Research Group.2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations.Pericardial effusion after cardiac surgery: incidence, site, size, and haemodynamic consequencesPrognostic significance of the oxygen uptake efficiency slope: percent-predicted versus actual value.Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium.Cardiopulmonary exercise testing is equally prognostic in young, middle-aged and older individuals diagnosed with heart failure.Defining the optimal prognostic window for cardiopulmonary exercise testing in patients with heart failure.Pulmonary hypertension in left heart disease.Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populationsOxygen transport in blood at high altitude: role of the hemoglobin-oxygen affinity and impact of the phenomena related to hemoglobin allosterism and red cell function.Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.Effect of bosentan on exercise capacity and clinical worsening in patients with dual down and eisenmenger syndrome.The lowest VE/VCO2 ratio during exercise as a predictor of outcomes in patients with heart failure.Does peak oxygen pulse complement peak oxygen uptake in risk stratifying patients with heart failure?The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development.The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: an evidence-based review.Prognostic value of flow-mediated dilatation following myocardial infarction.The partial pressure of resting end-tidal carbon dioxide predicts major cardiac events in patients with systolic heart failure.Determining the preferred percent-predicted equation for peak oxygen consumption in patients with heart failure.Endothelial dysfunction and pathophysiological correlates in atrial fibrillation.Influence of etiology of heart failure on the obesity paradox.Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review.Neuromuscular electrical stimulation and inspiratory muscle training as potential adjunctive rehabilitation options for patients with heart failure.The future of aerobic exercise testing in clinical practice: is it the ultimate vital sign?Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association.Effects of treatment strategy on endothelial function.Pulmonary hypertension with left-sided heart disease.Cardiopulmonary exercise testing: relevant but underused.Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II.Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I.Cardiopulmonary exercise testing in the assessment of pulmonary hypertension.Cardiopulmonary exercise testing is a core assessment for patients with heart failure.A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure.
P50
Q26865233-E7CC2EDF-74CA-4E71-ADD3-DDF176461591Q30252036-E4C00B4F-0A59-4B54-A836-F9E884FBA577Q30561803-D643F058-941F-435F-9F44-4FC0728EA612Q30961727-CC7876C7-FB27-480D-A008-D69343F26AFEQ31030359-15685039-06F6-49BC-809A-9A06B9674E92Q31089116-6739673A-4D76-427D-B619-5EE5AC358C87Q31089823-586A7564-A519-469A-AA7A-991C2C0AB954Q33614176-7848A97B-3213-4631-B754-8675E3C86D08Q33711345-1CF0A877-C118-4A53-9FAF-AA5A3094FFECQ34091110-FEF5E04E-ACD3-4C13-9A0C-A5BCD3A15B94Q34166467-7822DCB4-708A-4319-8DB8-3063717B2D36Q34192980-FA4497EB-84D0-4967-92E3-F3E3F1A9464DQ34314977-2A69131F-EFFB-4E58-8D0C-E45EAFEC41F5Q34337289-3810BBF5-2AA4-4324-91BB-64F00050C68BQ34375466-358FC3D3-6D74-42BC-A919-E0DAB4278E50Q34404495-B0F447AD-08CE-4481-AAE0-6F9821ED3D13Q35541155-45ACA531-EF30-406A-A2E6-3DA34D95DC70Q36357886-517DDB93-36D2-423F-B35D-49E8EC2DFA1AQ36611236-20DD09A8-576A-48D9-BEB0-056D4A78F004Q36623192-8CC65B90-9741-47B3-BC15-BD48BA089251Q36623224-EEC2DBE1-FB12-44FF-8B8A-6FB3861F1E9CQ36907334-9C398C7F-DF4B-40D7-B2A7-50A830CAA5F2Q36995244-5FD35639-7AAC-47C1-B339-05DBD63B76A5Q37052298-78D41839-C636-4558-849A-CAC13C9D9BCDQ37062978-71819364-1271-4AF1-B774-3AB0B39D7CF5Q37355560-1D7D7FD5-219F-4F93-A417-A298EB7C04D4Q37358474-4BE43D84-EA21-4229-BB44-7C843AD5D8EDQ37394595-E305548C-BFF4-4E7B-9211-46EC8027CFB7Q37647239-61F43FB1-D5C0-48BF-B4D3-D7FCB59A1925Q37662144-E8B2866B-AC8F-4CC4-B9B8-BB355AB45734Q37749825-62EB82ED-3A6F-4DA9-8F19-25CC61ECB33BQ37768298-7A07D806-4282-4F38-B7E3-EC7827752EA2Q37777209-83410E89-38C5-4C28-A416-847AC1976035Q37798155-E345492F-FFE0-4748-93C6-AD9A3D61EC21Q37810413-69280827-3096-48F5-A6E9-03A1B2301F9DQ37827023-05570D5F-B0B9-44BC-8302-42716A5F6559Q37832481-F2A5538B-1BBF-4403-BCC3-39A80DE80B14Q37867677-FAAF21C1-3B38-4798-AD62-9FD7C2D8F5FBQ37879226-10286B28-4EBB-4FAA-9870-FBB733F09C7AQ38021671-0A2ADF21-D909-4737-BD6D-EA4AC7CD73A0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Guazzi
@ast
Marco Guazzi
@en
Marco Guazzi
@es
Marco Guazzi
@nl
Marco Guazzi
@sl
type
label
Marco Guazzi
@ast
Marco Guazzi
@en
Marco Guazzi
@es
Marco Guazzi
@nl
Marco Guazzi
@sl
prefLabel
Marco Guazzi
@ast
Marco Guazzi
@en
Marco Guazzi
@es
Marco Guazzi
@nl
Marco Guazzi
@sl
P1053
J-3165-2016
P106
P1153
7102760456
P21
P31
P3829
P496
0000-0002-8456-609X